Selective clearance of SnCs via pharmacogenetic (CDKN2A‐DTR mice) or pharmacological (ABT263 or D+Q) approaches increased the survival time of tumor‐bearing mice and reshaped the TIME. This evidence concerns the gene CDKN2A and neoplasm.